FRI0204 Long-term benefits of 4-weekly certolizumab pegol monotherapy and combination therapy on household productivity and social participation in rheumatoid arthritis: 5-year results from an open-label extension study
Authors: V. Strand, O. Purcaru, R. van Vollenhoven, E. Choy, R. Fleischmann
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Certolizumab pegol (CZP) monotherapy administered every 4 weeks (Q4W) for rheumatoid arthritis (RA) has been shown to be associated with rapid and sustainable improvements in productivity up to 2 years.<sup>1</sup> <h3>Objectives</h3> To evaluate the long-term impact on household productivity and social participation of CZP 400mg Q4W, either as monotherapy or combined with other DMARDs, over 5 years. <h3>Methods</h3> In this open-label extension (OLE; NCT00160693) patients (pts) originally enrolled in FAST4WARD (NCT00548834) or Study 014 (NCT00544154) received CZP 400mg Q4W for 24 weeks (wks). Pts who completed or withdrew on/after Wk12 in either study were eligible to enter the OLE, and were permitted to take DMARDs in OLE. Household productivity and participation in family, social and leisure activities were assessed through the RA-specific Work Productivity Survey (WPS-RA); results are reported up to Wk268 (5.2 years). The analyzed population consisted of (1) CZP feeder study completers who received another DMARD at any point during either feeder or OLE studies (N=123; CZP combination completers) and (2) FAST4WARD CZP completers who entered OLE and did not receive any other DMARD at any point during either feeder or OLE studies (N=48; CZP monotherapy completers). Observed data is reported. <h3>Results</h3> In both populations analyzed, a rapid reduction in the number of days missed of household work per month was seen from feeder study baseline (BL) over 24 wks to OLE entry, and continued to decline over time up to 5 years (Table). A similar decrease was reported in the number of household days with reduced productivity per month, and in the rate of RA interference with household productivity per month. Increased participation in family, social and leisure activities was reported in both populations, with a decrease in the number of days missed per month from BL to OLE entry; these improvements continued during OLE. <h3>Conclusions</h3> CZP treatment, as monotherapy or in combination with other DMARDs, improved household productivity and increased participation in family, social and leisure activities. These improvements were maintained up to 5 years. <h3>References</h3> Strand V. Ann Rheum Dis 2011;70(6):996-1002 <h3>Acknowledgements</h3> The authors acknowledge Costello Medical Consulting for writing and editorial assistance which was funded by UCB Pharma. <b>Disclosure of Interest</b>: V. Strand Consultant for: UCB Pharma, O. Purcaru Employee of: UCB Pharma, R. van Vollenhoven Grant/research support from: Abbott, BMS, GSK, MSD, Pfizer, Roche, UCB Pharma, Consultant for: Abbott, BMS, GSK, MSD, Pfizer, Roche, UCB Pharma, E. Choy Grant/research support from: Abbott, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering-Plough, Synovate, UCB Pharma, Consultant for: Abbott, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering-Plough, Synovate, UCB Pharma, R. Fleischmann Grant/research support from: Genetech, Roche, Abbott, Amgen, UCB Pharma, Pfizer, BMS, Lilly, Sanofi-Aventis, Lexicon, MSD, Novartis, BiogenIdec, Astellas, AstraZeneca, Janssen, Consultant for: Roche, Abbott, Amgen, UCB Pharma, Pfizer, BMS, Lilly, Sanofi-Aventis, Lexicon, Novartis, Astellas, AstraZeneca, Janssen, HGS